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Introduction
Targeting strategies for cellular delivery of potential thera-
peutic agents, e.g., toxins,1 microRNAs,2 siRNAs,3 and 
antagomirs4,5 represent an emerging research ﬁeld.6 Typi-
cally, most of the molecules used for targeting approaches 
are antibodies, peptides, and lipids. However, aptamers rep-
resent a true versatile alternative in this regimen, as they are 
generated in vitro through appropriate selection procedures 
against various target structures, being either homogenous 
or complex.7–9 Most studies reporting the use of aptamers 
as targeting ligands employ the highly characterized aptamer 
A10, a 2′-ﬂuoro-2′-deoxy pyrimidine modiﬁed RNA molecule, 
which recognizes prostate-speciﬁc membrane-antigen on 
cancer cells.10 The A10 aptamer has extensively been tested 
as a delivery tool. For instance, it was covalently attached 
to nanoparticles with encapsulated chemotherapeutics and 
used to treat tumors in mice.11 Importantly, A10 not only binds 
its target molecule on the cell-surface of prostate tumors, but 
it also gets internalized into them. Thereby, A10 was shown 
to deliver its toxic nanoparticle cargo. Subsequently, the 
same A10 aptamer was shown to be also capable of car-
rying conjoined siRNA molecules into tumor cells, even in 
vivo, enabling speciﬁc mRNA knockdown activity.12 These 
ﬁndings nurtured the idea of using aptamers as common 
and generic targeting and delivering modules. Besides A10 
few aptamers have been used for delivery purposes, e.g., 
the nucleolin-binding aptamer AS1411.13 Likewise toxins14 
and nucleic acid-type15 of therapeutics, Levy and co-workers 
recently demonstrated that aptamers binding to DEC205 
on dendritic cells are enable to induce T-cells responses 
by delivering tumor-antigens.16 However, turning an in vitro 
selected aptamer into an in vivo functioning component 
can be a laborious task.17 From previous studies, it became 
evident that aptamers should meet certain requirements to 
qualify for delivery approaches.18 First, they should be short 
to be affordable at reasonable costs. Second, the structure 
should be stable over a broader range of temperatures and 
environmental conditions. Third, the aptamers should bear 
a certain ﬂexibility to allow the introduction of modiﬁcations 
(e.g., to optimize stability and half-life in vivo) and to equip 
them with other functionalities like imaging modalities and/
or siRNA molecules without losing their binding and uptake 
capabilities.
Herein, we report on a short DNA aptamer that recognizes 
selectively Burkitt’s lymphoma cells and bears an unusual 
G-quadruplex architecture. The aptamer provides a compact 
and stable structure, which allows its assembly with other 
aptamers, dyes, and nanoparticles, noteworthy without loss 
of function. We further show that the target cells speciﬁcally 
took up the aptamer via a clathrin-mediated endocytosis with 
a relatively fast kinetic, which opens the door for its utilization 
as a new modular delivery tool.
Results
We identiﬁed a series of aptamers recognizing Burkitt’s lym-
phoma cells.19,20 Here we provide an in-depth characteriza-
tion of one of the motifs found in the enriched DNA library, 
exempliﬁed by the aptamers C10, C06, and C08.20 This motif 
bears a G-rich segment (Figure 1), which suggests that the 
aptamer folds into a G-quadruplex structure. Besides, the 
G-rich segment, the motif comprises ﬂanking sequences built 
from two complementary nucleotide stretches (Figure 1), 
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which most likely serve as clamp (Figure 2a). To analyze this, 
we generated a variant of one of the aptamers (C10) made 
of only 36 nucleotides. This variant was named C10.36 and 
essentially covers the proposed G-quadruplex and clamp-
structure (Figure 2a). We performed circular dicroism (CD) 
spectroscopy to investigate whether C10.36 indeed resumes 
a G-quartet containing structure. These studies reveal that 
C10.36 most likely folds into a parallel G-quadruplex structure 
when compared to the control condition in the absence of ions 
(Figure 2b). We next used ﬂow cytometry and demonstrated 
that ﬂuorescently-conjugated C10.36 has preserved binding 
properties and recognizes Burkitt’s lymphoma cells, whereas 
a scrambled control sequence (C10.36sc) showed no bind-
ing (Figure 2c). To further delineate our ﬁndings, we synthe-
sized point mutants of C10.36 (Figure 2a) and tested their 
impact on the aptamer’s cell recognition properties. Based 
on our structural data and theoretical model, we introduced 
the following point mutations: G9A, G10A, G24A, G27A, and 
G28A (Figure 2a). The former three are expected to form 
part of the three-layer G-quadruplex structure, whereas the 
latter two not. Using ﬂow cytometry and Atto647N-labeled 
aptamers, we observed a drastic reduction in binding of the 
G-quartet mutants (G9A, G10A, G24A). However, mutations 
of G-residues outside of the proposed G-quadruplex (G27A, 
G28A) retained the aptamer’s cell-binding properties (Fig-
ure 2c). Even though CD-spectroscopy revealed formation 
of a G-quadruplex structure of mutant G24A  (Figure 2b), 
concentration-dependent measurements clearly indicate 
that compared to C10.36 this mutant lacks Burkitt’s lym-
phoma cell recognition properties (Figure 2d). Based on 
Figure 1 Sequence analysis depicted a G-rich motif (coloured orange) flanked by two complementary strands (coloured green). Variant 
nucleotides within the G-rich motif are depicted in bold.
Figure 2 The shortened aptamer C10.36 interacts with Burkitt’s lymphoma cells and folds into a G-quadruplex structure. (a) 
Predicted structure of C10.36, folding into a parallel G-quadruplex. Nucleotides are depicted as symbols as indicated. G9A and G24A (red) 
indicate point mutants that lead to loss of affinity, whereas point mutants G28A and G27A (green) show preserved binding capabilities (see 
also Supplementary Figure S1). (b) CD-spectrometry analysis of C10.36 (red curve) compared to HD1 (black curve), C10.36 G24A (purple 
curve, dashed), C10.36 ΔT14 (blue curve, dashed) and C10.36 (red curve, dashed) in pure H2O. (c) Interaction analysis using flow cytometry 
of 5′-Atto647N-labeled C10.36 mutants [200 nmol/l] (mutations as indicated) with Burkitt’s lymphoma cells compared to C10.36 (black bar, wt) 
and the non-binding control sequences C10.36 scramble (sc). D4s: truncated variant covering the sequence from nt 5 to 32. D8s: truncated 
variant covering the sequence from nt 9 to 28. GQ: truncated variant covering the sequence from nt 9 to 24 (G-quadruplex only). (d) Interaction 
analysis of 5′-Atto647N-labeled C10.36 (green bars) and the 5´-Atto647N labeled mutant G24A (orange bars) with Burkitt’s lymphoma cells. 
MFI, mean fluorescence intensity.
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these results, we propose that C10.36 comprises a three-
layer G-quadruplex structure arranged in a parallel orienta-
tion, as it has been described for other aptamers targeting 
the IL6R21,22 and the telomere ends of chromosomal DNA.23 
According to this model, nucleotide T14 might be bulged out 
to avoid interference with G-quartet formation (Figure 2a). 
Such an unusual arrangement of G-quadruplexes has been 
described recently.24,25 To further prove the impact of nucleo-
tide T14 on G-quadruplex formation and aptamer binding, 
we synthesized a deletion mutant (ΔT14). Flow cytometry 
and CD measurements on ΔT14 revealed that the lack of 
this thymidine-residue does neither interfere with quadruplex 
formation (Figure 2b) nor with aptamer binding to Burkitt’s 
lymphoma cells (Figure 2c).
In parallel to all mutation and deletions aforementioned, 
we synthesized variants of C10.36 bearing either locked 
nucleic acid (LNA)- or unlocked nucleic acid (UNA)-building 
blocks.26,27 All modiﬁed variants were equipped with a 5′-ﬂuo-
rescein moiety to enable ﬂow cytometry-based interaction 
analysis. C10.36 variants bearing LNA moieties embedded 
in the G-quadruplex structure (G16, G24) were found to no 
longer interact with the target cells (Figure 3a). This ﬁnding 
is in agreement with previous studies that report the loss of 
aptamer activity upon incorporation of LNA building blocks at 
positions that are engaged in G-quadruplex formation.28 We 
next extended our analysis toward three new aptamer vari-
ants bearing two LNA base pairs each, in the clamp region 
(G29,31; G31,32 and G29,30; Figure 3b). We also truncated 
the aptamer by shortening the stem size resulting in either 
four (G29,31; G31,32) or two remaining base-pairs (G29,30) 
(Figure 3b). These LNA-containing variants were found to 
retain binding to Burkitt’s lymphoma cells (Figure 3b). Nota-
bly, G29,30 represents the shortest variant of C10.36 (24 
nuclotides) but still capable of binding to cells. These ﬁnd-
ings indicate that the terminal stem structure is important for 
aptamer activity, but most likely it plays an important struc-
tural role rather than interacting directly with its target on the 
cell surface. In contrast to LNA, UNA-nucleotides provide 
a higher degree of ﬂexibility at the nucleic acid backbone. 
Therefore, we investigated if UNA nucleotides embedded 
at different positions within the G-quadruplex domain of 
C10.36 also affect the structure and activity of the aptamer. 
We replaced, one-by-one, the bridging T-residues (T12, T17 
and T21) of the quadruplex by UNA-nucleotides, as well as 
G9, G18, or G22 that seems to be involved in G-quadruplex 
formation. As shown in Figure 3c, all UNA-modiﬁed aptamer 
variants revealed loss of cell binding. This result indicates that 
the conformation of the G-quadruplex is essential for C10.36 
recognition properties and besides residue T14, which is 
abdicable no variations in this region are tolerable. However, 
Figure 3 Impact of LNA And UNA moieties on C10.36 binding to Burkitt’s lymphoma cells. (a) Replacement of residues G16 and G24 
(black circled) by LNA-variants leads to loss of binding. 5′-FAM labeled aptamer variants were used during flow cytometry analysis to detect 
cell binding. (b) Generation of truncated aptamer-variants with two LNA-moieties embedded in the stem structure (see also Figure 2a). Double 
modified variants G29,G31 (black box, no fill) and G31,G32 (yellow box) comprise 28 nucleotides whereas double modified variant G29,G30 
(blue box) comprises 24 nucleotides. (c) Interaction analysis of 5′-FAM labeled C10.36 variants with UNA moieties at the indicated (black 
circled) T- or G-positions. MFI, mean fluorescence intensity. UNA, unlocked nucleic acid; LNA, locked nucleic acid. Each variant was used at 
a concentration of 400 nmol/l.
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T14 points toward possible insertions of other entities, e.g., 
twisted-intercalating nucleic acids,29 which might allow to fur-
ther modulate the aptamer’s activity.
To this end, we describe a compact novel DNA aptamer, 
built from 36 nucleotides that recognize Burkitt’s lymphoma 
cells. Due to its compact and well-deﬁned structure, this 
aptamer might represent a valuable starting point for gen-
erating modular aptamer-directed delivery systems. For 
instance, combining the cellular binding activity of C10.36 
with another aptamer or with different nanoparticles. 
To investigate this, we started an endeavor to create an het-
ero-bivalent aptamer: C10.36 conjoined to a second DNA 
aptamer domain that binds streptavidin.30 The selection 
and characteristics of a streptavidin (SA)-binding aptamer 
are described in Supplementary Figure S1.30 The minimal 
motif of the SA-binding aptamer, named E5K5, bears 34 
nucleotides (Figure 4a). We conjoined this aptamer with 
the 3′-end of the cell binding aptamer C10.36 yielding a 
hetero-bivalent DNA aptamer, termed HA1 (Figure 4b). 
As controls, we synthesized hetero-bivalent variants of 
HA1 bearing mutations either in the SA- (HA1 ΔCGC) or in 
the cell-binding (HA1 GG9-10AA) domain (Figure 4b). HA1 
preserved binding properties of both domains, shown by ﬁl-
ter retention analysis of radioactively labeled HA1 to SA and 
competition experiments using ﬂuorescently labeled C10.36 
and increasing concentrations of HA1 (Supplementary  
Figure S1d,e, respectively). The synthesized control 
molecules behave as predicted and reveal either loss 
of cell- (HA1 GG9-10AA) or SA-binding (HA1 ΔCGC) 
 (Supplementary Figure S1). We next investigated the 
properties of HA1 to simultaneously interact with SA and 
cells. Therefore, we incubated HA1 with Burkitt’s lym-
phoma cells in the presence of ﬂuorescently labeled SA 
(SA-488) and monitored binding by ﬂow cytometry. These 
experiments show that HA1 simultaneously interacts with 
both target structures (Figure 4c). The control molecules 
did not reveal binding, clearly indicating the speciﬁcity of 
HA1  (Figure 4c). Having shown that HA1 performs in a 
predictable fashion, we went a step forward and shortened 
the bivalent aptamer further. We generated HA1.62 and 
HA1.54, which still were found to interact with SA, but to 
a lesser extend than HA1 (Supplementary Figure S1d). 
These data strongly suggest that due to its compact and 
stable structure C10.36 can be combined with other aptam-
ers to generate bi-functional molecules capable of binding 
simultaneously to different targets.
We extended our “lego-block”-approach toward chemical 
coupling methods and generated C10.36 or a nonbinding 
control oligodeoxynucleotide (G24A) equipped with quantum 
dots (QD). To covalently attach C10.36 to the QD-surface, 
we employed copper-free click chemistry.31 Brieﬂy, C10.36 
was synthesized bearing a 5′-azide moiety, which was then 
reacted with dibenzylcyclooctyne-derivatized QD (Figure 5a 
and Supplementary Figure S2). These QD were incubated 
with Burkitt’s lymphoma cells and binding was detected by 
ﬂow cytometry. As shown in Figure 5b, QD equipped with 
C10.36 recognize the target cells, whereas QD derivatized 
with the mutant G24A exhibited only background binding. 
Figure 4 Assembly of hetero-bivalent aptamers. (a) Secondary structure of the DNA aptamer E5K5 (see also Supplementary Figure 
S1) that interacts with streptavidin (SA) and a schematic of the Burkitt’s lymphoma cell-binding aptamer C10.36. The green box with white G 
indicates the G-quadruplex. Nucleotides are depicted by color code, as indicated. (b) Assembly of the hetero-bivalent aptamer HA1 built from 
C10.36 and E5K5 (top) and the control aptamers HA1 ΔCGC (middle, loss of nucleotides 55-57) and HA1 GG9,10AA (bottom, double point 
mutants indicated by bites in green box). (c) Interaction analysis of HA1 (black bar), HA1 ΔCGC (yellow bar) and HA1 GG9,10AA (green bar) 
with Burkitt’s lymphoma cells in the presence of SA-488 at indicated concentrations.
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These data further indicate the versatility of C10.36 being 
compatible to different modiﬁcations and, thus, applications 
without loss of cell-recognition properties. Advantageously, 
one QD is equipped with several aptamers, thus leading to 
a low detection limit of 1 nmol/l compared to monovalent 
 interactions most likely reﬂecting the multivalency effect 
 (Figure 5b).
We next investigated the fate of C10.36 upon target cell 
recognition. We therefore performed microscopy studies, 
employing Atto674N-modifed C10.36 or the nonbinding 
control (G24A) to visualize association of the aptamer with 
Burkitt’s lymphoma cells. After incubation of C10.36 with 
cells, a clear uptake of the ﬂuorescent aptamer but not of 
the nonbinding control G24A was observed (Figure 6a,b). 
The kinetics of aptamer-uptake was shown to be rapid, 
with a maximum yield being achieved after only 15 minutes 
 (Supplementary Figure S3). To elucidate the underlying 
endocytotic mechanism by which C10.36 is entering the cells, 
we performed colocalization studies with ﬂuorescently labled 
transferrin and dextran. In these studies, we coincubated 
Burkitt’s lymphoma cells with Atto647N-labeled C10.36 and 
Alexa488-labeled transferrin or dextran. The C10.36 aptamer 
colocalizes with dextran and transferrin (Figure 6c,d). The 
uptake of transferrin receptors occurs via clathrin-mediated 
endocytosis.32 However, dextran molecules can enter via 
clathrin-mediated endocytosis but also using caveolin- 
mediated endocytosis, phagocytosystosis, or macropinocy-
tosis depending on the cell type.33 Therefore, we incubated 
the cells with C10.36 and the clathrin-mediated endocytosis-
blocker Dynasore,34 which resulted in a signiﬁcant reduction 
of aptamer internalization (Supplementary Figure S3). This 
further supports the hyposthesis that C10.36 enters into cells 
predominantly via clathrin-mediated endocytosis. Finally, to 
corroborate the speciﬁcity of C10.36 for Burkitt’s lymphoma 
cells, we tested it on different lymphoma-derived cell lines. 
In these experiments, C10.36 was found to be highly spe-
ciﬁc, as it internalized only in Ramos Burkitt’s lymphoma cells 
and under the applied conditions no signiﬁcant uptake was 
observed in Raji, Jurkat, or P12 cells (Figure 7).
Discussion
The described aptamer C10.36 is a short single-chained 
DNA molecule that recognizes and internalizes speciﬁcally 
into Burkitt´s lymphoma cells (Ramos cell line). Colocaliza-
tion and toxin studies revealed that the aptamer most likely 
hijacks a clathrin-mediated endocytotic pathway, via a yet 
unknown cell surface molecule. In this way, C10.36 repre-
sents a potential delivery vehicle for cargo transport; here we 
provide evidence that it can be coupled to ﬂuorescent small 
molecules, QD and a second SA-binding aptamer. If this 
strategy can be adapted towards delivering toxins or nucleic 
acid-type of therapeutics,13 e.g., siRNAs and antagomirs, will 
be examined in follow up studies. This type of delivery strate-
gies has been performed using mainly the prostate-speciﬁc 
membrane-antigen-speciﬁc aptamer A10, which is also 
taken up through a clathrin-dependent endocytotic mecha-
nism.12 Alternatively, some other aptamers were developed 
to serve as delivery vehicles, e.g., a transferrin receptor-spe-
ciﬁc aptamer,35 T-cell recognizing aptamers15 and AS1411 
(ref. 36), a pan-tumor cell acting homodimeric DNA molecule. 
However, in most cases, the delivery efﬁciency, required for 
activtiy of associated cargo-RNA, is limited and far from opti-
mal yet.4 Typically, endocytosis leads to the trapping of the 
cargo-molecule in the endosomal lumen and, thus, diminish-
ing their potential activity.37 In this regard, endosomal escape 
strategies may be needed, which have not been established 
using aptamer-based delivery systems to date.38
The C10.36 aptamer folds into a compact G-quadruplex 
structure bearing an uncommon topology. This type of topol-
ogy has been recently described where the formation of 
quadruplexes was facilitated by out-bulged residues.25 In 
aggrement with such report, our study demonstrates that 
Figure 5 (a) Atomic force microscopy images (top) and height distributions (bottom) of QD, QD-C10.36, and QD-G24A. (b) Interaction 
analysis using flow cytometry of QDs derivatized with C10.36 (green bars) or C10.36 G24A (24A, red bars) with Burkitt’s lymphoma cells at 
different QD concentrations (0.3 - 3 nmol/l).
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a simple repetitive run of G-residues is not the sole crite-
ria for deﬁning G-quadruplexes and that this is also true for 
G-quadruplexes found in aptamers, as shown in this study 
for the ﬁrst time. The compact structure of C10.36 enables 
its modular assembly with other aptamers or nanoparticles; 
exempliﬁed by the combination of C10.36 with a streptavidin-
binding aptamer and quantum dots. Assemblies of aptamers 
with other molecules and particles represent valuable tools 
for generating higher order architectures and multifunctional 
molecules. The “lego-block”-type assembly, in which compo-
nents are conjoined and exchanged modularly, is beneﬁcial 
for rapid conﬁrmation strategies alleviating cumbersome opti-
mization processes. Especially a combination with SA-bind-
ing domains allows to exchnage cargos rapidly without further 
engineering efforts, as biotinylated molecules can be easily 
assembled with the complex. Other investigations generated 
these assemblies by using adaptor oligonucleotides to which 
different modules can hybridize.39–41 However, this method 
relies on a noncovalent interaction, thus less stable assembly 
with greater synthesis and generation efforts. In either case 
aptamers that have a compact, stable, and short sequence 
length, as revealed by C10.36 are optimal. C10.36 was also 
tolerant toward implementation of LNA building blocks, as 
long as they do not interfere with G-quartet formation. Modiﬁ-
cation of known aptamers by introduction of LNA nucleotides 
has been performed in attempts to improve aptamer prop-
erties. For instance, a Tenascin-C binding aptamer demon-
strated increased stabilization of the aptamer in serum and 
maintained strong binding to Tenascin-C of the LNA-contain-
ing aptamer.42 While implementation of LNA improves serum 
Figure 6 Cell staining and the endocytic pathway used by C10.36 aptamer. (a) Epifluorescence images of RAMOS cells live stained 
with Atto647N labeled C10.36 or control aptamer G24A (see methods). (b) Quantification of cellular fluorescence after staining with Atto647N 
labeled C10.36 or the G24A mutant aptamer. Error bars represent the s.e.m of 3 independent experiments (**** = P < 0.0001, Student´s 
t-test). (c) Confocal images of Ramos cells co-incubated with fluorescent transferrin (Tf-A594 or Tf-A488), dextran (Dx-A488) and Atto647N 
labeled C10.36. (d) Pearson’s correlation coefficient was used to evaluate the coincidence detection between the coincubated molecules in 
c). Coincubation of Tf-A594 and Tf-A488 (Tf-Tf) provide the maximal expected correlation (positive control). Negative control was obtained by 
inverting one of the images resulting in random Pearson’s correlation values. Error bars represent the s.e.m of 3 independent experiments.
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stability, our study delineates that LNA building blocks allows 
further truncation of the aptamer’s stem structure to yield a 
shorter but still active aptamer. Likewise, UNA has demon-
strated utility in aptamer structures.26 Due to its more ﬂexible 
nature, UNA has the potential to alleviate strain in structures 
with loops as conﬁrmed by UNA modiﬁcation of the loops of 
a thrombin binding quadruplex aptamer. However, incorpo-
ration of UNA abolished C10.36 cell-targeting properties, at 
least in respect of the nucleotide positions investigated.
The adaptability of C10.36 to different modiﬁcations and 
combinations with other components opens a multitude of 
downstream applications. For example, quantum dots equipped 
with C10.36 may be useful as diagnostic tools. We could dem-
onstrate in this study that QD-C10.36 conjugates enable the 
sensitive detection of Burkitt’s lymphoma cells. This likewise 
opens the path toward multiplex analysis in combination with 
other available aptamers.43 However, it remains to be deter-
mined whether C10.36 also recognizes Burkitt’s lymphoma 
cells derived from patient samples and in respect of therapeu-
tic endeavors reveals in vivo activity. To this end, we provide a 
thorough characterization of C10.36, its utility as valuable tool 
for detection, delivery and assembly of multifunctional devices 
for cell-targeting approaches. Albeit its molecular target is not 
known to date and which will be unraveled in ongoing studies 
using aptamer-based afﬁnity labeling,44 we believe that C10.36 
represents an useful tool for biomedical research, diagnostics, 
and developing targeted therapies.
Materials and methods
Cells. Human Burkitt’s lymphoma cell line RAMOS was kindly 
provided by Professor Marianne Hokland from the Institute of 
Biomedicin, Aarhus University. RAMOS cells were cultured at 
37 °C and 5% CO2 in RPMI 1640 media supplemented with 
10% fetal bovine serum and 1% penicillin/streptomycin.
Flow cytometry. Flow cytometry results were obtained from a 
BD FACSCanto cytometer. For binding experiments, 2 × 105 
Ramos cells were incubated with aptamers in the respective 
concentrations in 100 μl of binding buffer (RPMI 1640 supple-
mented with 10% fetal bovine serum and 1 mg/ml of sheared 
sperm salmon DNA (sssDNA)) for 15 minutes at 37 °C and 
5% CO2. The cells were then washed three times with Hank′s 
Balance salt solution (Gibco Life Technologies, Karlsruhe, 
Germany)  using centrifugation at 200 g for 5 minutes at room 
temperature. For the measurement, the cell pellet was resus-
pended in 200 μl Hank′s Balance salt solution and ~104 cells 
were analyzed in the ﬂow cytometer. The data were postana-
lyzed using FlowJo software. Flow cytometry for aptamers 
and QD-derivatized aptamers were done according to the 
follwing protocol: Approximately 200,000 Ramos cells were 
suspended in 150 μl media in 48-well plates and incubated 
with different amounts of aptamer conjugated QDs for 4 hours 
in cell culture medium (0.33, 1, or 3 nmol/l QD). The cells 
were then centrifuged, washed with phosphate buffer saline 
(PBS), and the cells were resuspended in PBS containing 
1% formaldehyde. Flow cytometry was done using a Gallios 
Flow Cytometer from Beckman Coulter. The cell count was 
5,000 and the FL4 channel was used for detection of the QD 
signal. Data were analyzed using Kaluza Analysis Software. 
Results are represented as mean ﬂuorescence intensity and 
standard deviation, normalized to unmodiﬁed QD, n =3.
UNA and LNA oligonucleotide synthesis. Oligonucleotides 
were synthesized in 1.0 μmol scale using standard phosphor-
amidite chemistry on an automated nucleic acid synthesizer. 
LNA phosphoramidites were purchased from Exiqon (www.
exiqon.com) and UNA phosphoramidites from RiboTask 
(www.ribotask.com). The synthesis conditions used were as 
follows: trichloroacetic acid in CH2Cl2 (3:97) as detritylation 
reagent; 0.25 M 4,5-dicyanoimidazole in CH3CN as activator; 
acetic anhydride in Tetrahydrofuran (THF) (9:91, v/v) as cap 
A solution; N-methylimidazole in THF (1:9, v/v) as cap B solu-
tion. As an oxidizing solution 0.02 M iodine in H2O/pyridine/
THF was used for phosphate linkages whereas a thiolation 
solution 0.02 M PADS (phenylacetyl disulﬁde) in 3-picoline/
acetonitrile (1:1, v/v) was used for phosphorothioate link-
ages. Coupling times used were 12 minutes for incorporation 
of LNA, UNA, and DNA monomers. The stepwise coupling 
yields (~99% per step) were determined from the absor-
bance of the dimethoxytrityl cations (DMT+) released after 
each coupling step. Cleavage from the support was carried 
out by using 32% aqueous ammonia solution, 12 hours at 
55 °C. All oligonucleotides were puriﬁed by reversed phase 
HPLC (RP-HPLC) using a Waters 600 system equipped with 
an XBridge OST C18 (2.5 μm, 19 × 100 mm) column and 
an XBridge Prep C18 (5 μm, 10 × 10 mm) precolumn. After 
Figure 7 Cellular specificity of the C10.36 aptamer.  (a) 
Examples of confocal images obtained from different cell lines. The 
upper row of images shows the fluorescent signal of cells stained for 
1 hour at 37 °C with 200 nmol/l of C10.36-Atto647N (see Methods for 
details). The lower row of images shows the overlay of fluorescence 
signal and transmission light. Note that the C10.36 signal in RAMOS 
cells is clearly intracellular. (b) Quantification of C10.36 and control 
aptamer signal for the different cell lines. Error bars represent the 
s.e.m from three independent experiments (~10 cell per experiment).
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removal of the DMT-group, oligonucleotides were charac-
terized (purity >90%) by ion exchange HPLC (IE-HPLC) on 
a Dionex system HPLC (VWR) and their composition veri-
ﬁed by matrix-assisted laser desorption ionization time-of-
ﬂight mass spectrometry (MALDI-TOF) on a Microﬂex Maldi 
(Bruker instruments, Leipzig, Germany).
SELEX. Selection of streptavidin (SA)-binding DNA aptamer 
was done according to the previous experiments.30,45,46 Brieﬂy, 
a DNA library was incubated with SA-derivatized magentic 
beads (Dynal) and after removal of nonbound sequences, 
the bound sequences were recovered by heat denaturation 
followed by polymerase chain reaction and single strand 
generation by λ exonuclease digestion. As selection buffer 
PBS, supplemented with 3 mmol/l MgCl2 was used. After 
10 selection cycles, the enriched library was cloned and 
sequenced. We employed the following aptamer DNA library: 
5′-AGCATAGAGACATCTGCTATTGGTAGCACA-N25-TGTG 
CAACCG TAGACTCCAGACTTCAGGTA-3′ and for polyme-
rase chain reaction, the following primer molecules were used: 
ADMA4.20 (fw) 5′-AGC ATA GAG ACA TCT GCT AT-3′; ADMA 
4.20.Phos (rev) 5′-Phos-TAC CTG AAG TCT GGA GTC TA-3′.
Filter retention analysis. To assess apatmer biding to strepta-
vidin, we employed ﬁlter retention analysis using 5′-radioac-
tively labeled DNA molecules (32-P) according to a previously 
reported protocol.47
Azide modiﬁcation of aptamers. Aptamer sequences 
C10.36 and G24A containing a 5′-amino-modiﬁer-C6 were 
synthesized by DNA Technology A/S. 40 nmol C10.36 
or G24A (1 mmol/l stock), 80 μl 4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid buffer (0.1 M, pH 8.0), and 2 
μmol azido-dPEG8-NHS (Quanta Biodesign) were mixed and 
incubated overnight at room temperature on a shaking plate 
at 500 rpm. Not coupled azido-dPEG8-NHS was removed 
from the supernantant after aptamer was precipitated. For 
ethanol precipitation of the aptamer, the concentration of 
sodium acetate was adjusted to 0.3 M and a 2.5-fold vol-
ume of ethanol (99.9%) added to the sample. The sample 
was stored at room temperature for 30 minutes followed by 
30 minutes on dry ice. The sample was then centrifuged at 
14,000 rpm for 15 minutes at 4 °C and the supernatant was 
discarded. Two hundred microliters of of 70% ethanol were 
added and the sample was centrifuged at full speed for 5 
minutes. The supernatant was removed and the aptamer was 
dissolved in PBS supplemented with 0.5 mmol/l MgCl2. The 
azido-modiﬁed aptamer was stored at −20 °C.
Aptamer conjugation to QDs. First, dibenzylcyclooctyne 
(DBCO) modiﬁed QDs were made by mixing 200 pmol Qdot 
705 ITK amino (Polyethylene glycol) quantum dots (QD, Life 
Technologies) (8 μmol/l solution in 50 mmol/l borate, pH 8.3) 
with 200 nmol DBCO-NHS ester (Jena Biosciences) in 30% 
dimethyl sulfoxide overnight on a shaking plate (500 rpm) at 
room  temperature. Buffer exchange was performed with a 
Nanosep 100 K Omega centrifugal devices (Pall Corporation) 
and the QDs were washed four times with PBS containing 0.5 
mmol/l MgCl2 to ﬁnally resuspend them in 100 μl PBS con-
taining 0.5 mmol/l MgCl2. The DBCO functionalized QDs were 
then mixed with C10.36 or G24A bearing a 5′-azide moiety in 
a total volume of 50 μl PBS containing 0.5 mmol/l MgCl2 and 
10% dimethyl sulfoxide. The reaction was incubated over-
night at 50 °C (2 nmol aptamer/17 pmol QD-DBCO for the 
cell binding study and 2 nmol aptamer/29 pmol QD-DBCO 
for the atomic force microscopy (AFM) study). Enreachment 
and washing of aptamer-conjugated QD were achieved using 
Nanosep 100 KDa (MWCO). Final aptamer-functionalized 
QD were resuspended in PBS + 0.5 mmol/l MgCl2. Samples 
were then centrifuged 2 minutes at 10,000 rpm to remove 
aggregates and the samples were stored at 4 °C. The QD 
concentration was determined by ﬂuorescence spectroscopy 
using a Fluorimax 3 (Jobin Yvon) by comparing to a standard 
curve made from different concentrations of unmodiﬁed QDs 
in PBS. The samples were excited at 530 nm and emission 
measured at 705 nm.
AFM. All AFM images were recorded under ambient condi-
tions with a commercial AFM MultiMode VIII (Bruker, Santa 
Barbara). Experiments were performed in tapping mode at 
a scan frequency of 1 Hz with optimized feedback param-
eters. Ultrasharp silicon cantilevers (OMCL-AC160TS-R3; 
Olympus) with a nominal spring constant of 26 Nm−1 were 
used. Muscovite mica, which was freshly cleaved by adhe-
sive tape before each experiment, was used as the substrate. 
All the images and size distributions were analyzed by using 
the commercial software Scanning Probe Image Processor 
(Image Metrology, Denmark).
Aptamer staining. Ramos cells were cultured as descried 
above. Cells were tipically incubated at 37 °C for 1 hour with 
200 nmol/l of Atto647N coupled C10.36 or G24A. All incuba-
tion were performed in complete medium (RPMI medium 
(PAA Laboratories GmbH, Paching, Austria) with 5% fetal calf 
serum (PAA), 2 mmol/l L-Glutamine and 100 U/ml of penicil-
lin and streptomycin) supplemented with 1 mg/ml of sheared 
sperm salmon DNA (Invitrogen). For the colocalization studies 
 (Figure 6c,d), 200 nmol/l of C10.36 aptamer was coincubated 
at 37 °C with 50 μg/ml of transferrin-Alexa488 for 20 minutes or 
100 μg/ml of dextran-Alexa488 (10 kDa) for 20 minutes. Posi-
tive control was performed by coincubation of 50 μg/ml of each 
transferrin-Alexa488 and transferrin-Alexa594 for 20 minutes. 
For the inhibition of clathrin-mediated endocytosis, cells were 
pretreated with 80 μmol/l dynasore (Sigma-Aldrich) and 1 mg/
ml of sssDNA in complete medium for 15 minutes inside the 
incubator (37 °C and 5% CO2). After one washing step, cells 
were incubated with 200 nmol/l of aptamer (C10.36 or G24A) in 
presence of 80 μmol/l dynasore and 1 mg/ml of sheared sperm 
salmon DNA in complete medium for 20 minutes. After the 
staining incubations, cells were washed thoroughly in Dulbec-
co’s PBS (DPBS) and ﬁxed in ice-cold 4% paraformaldehyde 
for 30 minutes while centrifuging (300 g at 4 °C) on poly-L-
lysine-coated glass coverslips. After washing with DPBS, the 
remaining active formaldehyde groups were quenched by incu-
bating the cells in DPBS supplemented with 0.1 M glycine and 
0.1 M NH4Cl for 15 minutes at room temperature in the dark. 
After a brief washing with DPBS, cells were mounted on glass 
slides using Mowiöl solution (6 g glycerol; Merck Millipore, 6 ml 
deionized water, 12 ml 0.2 M Tris buffer pH 8.5, Merck Millipore, 
2.4 g Mowiöl 4–88; Merck Millipore).
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Microscopy. Conventional epiﬂuorescence images were 
obtained (Figure 6a and Supplementary Figure S3) with 
an Olympus IX71 microscope equipped with 0.75 NA/40×, 
1.35 NA/60×, and 1.45 NA/100× objectives. Images were 
captured with an Olympus F-View II CCD camera (all from 
Olympus, Hamburg, Germany).
Confocal images (Figures 6c and 7) were obtained using 
a True Confocal System STED SP5 ﬂuorescence micro-
scope (Leica Microsystems GmbH, Mannheim, Germany), 
equipped with a 1.4 NA/100× STED objective (Leica). Images 
were scanned unidirectionally at 1 kHz with the pinhole set to 
one Airy unit.
Image analysis and statistics. Data analysis was performed by 
custom-written procedures, in Matlab (The Mathworks, Natick, 
MA). Cell intensities (Figure 6b and Supplementary Figure 
S3) were assessed by manually selecting the background and 
cell. All values are given in mean ± standard error of the mean. 
Graphs and statistical analysis were carried out with Graph-
Pad Prism 5.0 (GraphPad Software, San Diego, CA).
Supplementary material
Figure S1.Characterisation of a streptavidin binding aptam-
er and its conjunction to C10.36.
Figure S2. Reaction scheme showing aptamer functional-
ization of QDs by copper-free click chemistry.
Figure S3. Internalization kinetics of C10.36 and the effect 
of the endocytosis inhibitor dynasore.
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